Radio and PodcastLive Radio & PodcastsScience & Medicine
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disea...
About This Episode
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings is...
Podcast
This episode belongs to PeerVoice Clinical Pharmacology Video.
Listen Online
Use the player on this page to stream the episode online.
Episode Details
Published Jan 7, 2026, 00:21:47 long, audio available.
Related Episodes
Continue listening to more episodes from PeerVoice Clinical Pharmacology Video.
Questions About This Episode
What is Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings about?
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings
Where can I listen to Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings?
You can listen to Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings online on Radio and Podcast. Open the player on this page to stream the available audio.
Which podcast is Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings from?
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings is an episode from PeerVoice Clinical Pharmacology Video by PeerVoice, 1140 Avenue of the Americas, 15th Floor, New York, NY 10036.
How long is this episode?
This episode is 00:21:47 long.
When was this episode published?
This episode was published on Jan 7, 2026.
Can I save Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings for later?
Yes. Use the heart button on the episode page to add it to your favorite episodes list.
Are there related episodes from PeerVoice Clinical Pharmacology Video?
Yes. This page shows related episodes from PeerVoice Clinical Pharmacology Video when more episodes are available from the podcast feed.
Quick Answers About This Episode
Where can I listen to Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings?
You can listen to Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings on this page when the episode audio is available from the podcast feed.
Which podcast is this episode from?
Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings is from PeerVoice Clinical Pharmacology Video by PeerVoice, 1140 Avenue of the Americas, 15th Floor, New York, NY 10036.
What are the episode details?
Published Jan 7, 2026 and 00:21:47 long